Trial Profile

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Resiquimod Sulfate (Primary) ; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms TeLuRide-005
Sponsors Eikon Therapeutics

Most Recent Events

20 Jul 2026 According to an Eikon Therapeutics media release, data from the trial will be presented at the 2026 European Society of Medical Oncology (ESMO) Congress
31 May 2026 Results presented in an Eikon Therapeutics Media Release.
31 May 2026 According to an Eikon Therapeutics media release, data from this study was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com